SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Venus Remedies gets Japan patent office’s approval for Vancoplus

06 Feb 2012 Evaluate

Venus Remedies has achieved another landmark by fetching its first patent grant from Japan patent office (JPO) which is among the most stringent pharma market in the world. This patent has been granted for its novel research product Vancoplus which has been designed to curb the growing bacterial resistance specially caused by the notorious MRSA strain which is usually termed as one of the Superbugs.

During the past four decades, Methicillin- Resistant Staphylococcus Aureus (MRSA) has evolved from a controllable nuisance into a serious public health concern. Vancoplus is the only known remedy to control MRSA, VRSA (Vancomycin Resistant Staphylococcus Aureus) and multi drug resistant bacteria which causes meningitis, pneumonia, typhoid, septicemia, urinary tract infection, skin and skin infections and staphylococcal endocarditic.

The market size of MRSA in the world accounts for about $900 million, presently, it is growing with CAGR of 4.8 percent, which is estimated to reach to $1.2 billion by 2017.

The company intends to launch this research product in early 2015. Currently, Vancoplus is available in emerging markets and is under registration ion many countries. Venus intends to out-license Vanocoplus across patent protected regions to major pharmaceutical players.

Venus Remedies Share Price

1006.60 36.70 (3.78%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×